Not applicableUnknownNCT05527808What this trial is testingA Single-arm Exploratory Study of Neoadjuvant TherapyWho this might be right forLung Adenocarcinoma Jun Liu 28
Testing effectiveness (Phase 2)UnknownNCT03410784What this trial is testingPembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube CancerWho this might be right forOvarian Cancer National Cancer Institute, Naples 72
Not applicableStudy completedNCT03788746What this trial is testingPrevalence of PD-L1 Expression in Patients With Advanced Urothelial CarcinomaWho this might be right forUrothelial Carcinoma AstraZeneca 181
Not applicableUnknownNCT03078959What this trial is testingPrognostic Value of PD-L1 in NSCLCWho this might be right forCarcinoma, Non-Small-Cell Lung Fondazione Ricerca Traslazionale 350
Large-scale testing (Phase 3)Active Not RecruitingNCT03003962What this trial is testingStudy of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)Who this might be right forNon Small Cell Lung Carcinoma NSCLC AstraZeneca 669
Testing effectiveness (Phase 2)Looking for participantsNCT06769698What this trial is testingSee if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaWho this might be right forHead and Neck Squamous Cell Carcinoma (HNSCC) Regeneron Pharmaceuticals 120
Not applicableUnknownNCT03495544What this trial is testingStudy Estimating Association Between Germline Mutations and PD-L1 Expression in Breast CancerWho this might be right forHereditary Breast Cancer Tatarstan Cancer Center 390
Early research (Phase 1)Study completedNCT02999477What this trial is testingChanges In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast CancerWho this might be right forBreast Cancer Adrienne G. Waks 32
Testing effectiveness (Phase 2)Active Not RecruitingNCT06727565What this trial is testingStudy of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01Who this might be right forHead and Neck Squamous Cell Carcinoma Gilead Sciences 39
Not applicableUnknownNCT05964595What this trial is testingTemporal Diffusion Spectroscopy MRI in Predicting the CPS of PD-L1 Expression and the Efficacy of Neoadjuvant TherapyWho this might be right forHead and Neck Squamous Cell CarcinomaMagnetic Resonance ImagingNeoadjuvant Therapy Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 136
Testing effectiveness (Phase 2)Looking for participantsNCT06269211What this trial is testingNeoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive ExpressionWho this might be right forCarcinoma, Non-Small-Cell Lung Ruijin Hospital 29
Testing effectiveness (Phase 2)Ended earlyNCT02934503What this trial is testingStudy of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)Who this might be right forSmall Cell Lung Cancer (SCLC) NYU Langone Health 5
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07818304What this trial is testingSRT Combined With Envafolimab and Endostar in the First-line Treatment of Advanced NSCLCWho this might be right forNon Small Cell Lung CancerLung Neoplasms The First People's Hospital of Lianyungang 61
Not applicableNot Yet RecruitingNCT07515313What this trial is testingExpression of CD274 (PD-L1) and CD276 in B-cell Malignancies: A Study by FlowcytometryWho this might be right forB-cell Malignancies Assiut University 159
Very early researchStudy completedNCT02978196What this trial is testing99mTc/68Ga Labeled Anti-PD-L1 sdAb in Assessment of PD-L1 Expression in NSCLCWho this might be right forNon-Small Cell Lung Cancer Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 34
Testing effectiveness (Phase 2)Active Not RecruitingNCT06939452What this trial is testingA Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 ExpressionWho this might be right forAdvanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma Yongxu Jia 37
Not applicableStudy completedNCT04253080What this trial is testingExpression of IL4 Induced Gene 1 in Patients With Cutaneous Melanoma: Value in Prognosis and/or in Predictive Response to Immune Checkpoint InhibitorsWho this might be right forCutaneous Melanoma Assistance Publique - Hôpitaux de Paris 127
Not applicableUnknownNCT03701607What this trial is testingEffect of Chemotherapy on PD-L1 in NSCLCWho this might be right forChemotherapyImmunotherapyPD-L1 Baodong Qin 30
Testing effectiveness (Phase 2)WithdrawnNCT05234606What this trial is testingA Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid TumorsWho this might be right forUrothelial CarcinomaTriple Negative Breast CancerNon-small Cell Lung Cancer+2 more Silverback Therapeutics
Not applicableUnknownNCT05428111What this trial is testingExpression of Programmed Death-1 (PD-1) & Programmed Death Ligand-1 (PDL-1) in Acute Lymphoblastic Leukemia in PediatricWho this might be right forAcute Lymphoblastic Leukemia in Pediatric Sohag University 50